ArticleInternational journal of clinical and experimental pathology2019
Detection of serum long non-coding RNA UCA1 and circular RNAs for the diagnosis of bladder cancer and prediction of recurrence.
Article in International journal of clinical and experimental pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 21 citations in OpenAlex.
- Blood-based liquid biopsy: insights into early detection, prediction, and treatment monitoring of bladder cancer.Cellular & molecular biology letters · 2023Review
- The Roles of miRNAs in Predicting Bladder Cancer Recurrence and Resistance to Treatment.International journal of molecular sciences · 2023Review
- Serum LINC00152 and UCA1 in HCV-Induced Hepatocellular Carcinoma: Clinical Significance and Prognostic Value.Biologics : targets & therapy · 2023Article
- Circular RNA circFARSA promotes the tumorigenesis of non-small cell lung cancer by elevating B7H3 via sponging miR-15a-5p.Cell cycle (Georgetown, Tex.) · 2022Article
- Oncogenic Dysregulation of Circulating Noncoding RNAs: Novel Challenges and Opportunities in Sarcoma Diagnosis and Treatment.Cancers · 2022Review
- Article
- The Role of Circular RNAs in the Carcinogenesis of Bladder Cancer.Frontiers in oncology · 2022Review
- Regulatory role of long non-coding RNA UCA1 in signaling pathways and its clinical applications.Oncology letters · 2021Review
- Circulating Long and Circular Noncoding RNA as Non-Invasive Diagnostic Tools of Hepatocellular Carcinoma.Biomedicines · 2021Review
- Long Non-Coding RNAs in Diagnosis, Treatment, Prognosis, and Progression of Glioma: A State-of-the-Art Review.Frontiers in oncology · 2021Review
- Diagnostic and Prognostic Value of Circulating CircRNAs in Cancer.Frontiers in medicine · 2021Review
- Circular RNAs and Bladder Cancer.OncoTargets and therapy · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accumulating evidence indicates that long noncoding RNAs (lncRNAs) and circular RNAs (circRNAs) may be biomarkers for the diagnosis and prediction of recurrence in tumor patients because they play an important role in tumorigenesis and progression. In this study, the expression of lncRNA urothelial carcinoma-associated 1 (UCA1) and associated circFARSA, circSHKBP1, and circBANP was investigated in serum specimens from bladder cancer (BC) patients and healthy controls using real-time PCR. When comparing patients with BC to healthy controls, the expression of lncRNA UCA1, circFARSA, and circSHKBP1 was significantly increased. The area under the curve (AUC) of the lncRNA UCA1 and circSHKBP1 signature to distinguish BC patients from controls was 0.804. The diagnostic performance of this signature was more optimal for low volume tumors (AUC = 0.870). Moreover, we determined that the expression of circFARSA, circSHKBP1, and circBANP was higher for recurrent BC than for patients without recurrence. Receiver operating characteristic (ROC) analysis revealed that a combination of circFARSA and circBANP levels was able to discriminate the patients with tumor recurrence from those without, with an area under the ROC curve of 0.737. In conclusion, our results identified an lncRNA UCA1: circSHKBP1 panel and a circFARSA: circBANP panel for BC diagnosis and prognosis, respectively.
Indexed as
Identifiers
31934131PMC6949697W3005060270What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.